BIOGEN INC. is 1.8x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($28.68 B vs $16.17 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NBIX | BIIB |
|---|---|---|
| Market cap | $16.17 B | $28.68 B |
| US-listed rank | #700 | #476 |
| Revenue (latest FY) | $2.86B | $9.89B |
| Net income (latest FY) | $478.60M | $1.29B |
| Net margin | 16.7% | 13.1% |
| P/E (trailing FY) | 33.8 | 22.2 |
| SEC filings | 2,097 | 2,690 |
BIOGEN INC. is 1.8x more valuable than NEUROCRINE BIOSCIENCES INC by market capitalization ($28.68 B vs $16.17 B).
In their latest fiscal years, NEUROCRINE BIOSCIENCES INC reported $2.86B in revenue while BIOGEN INC. reported $9.89B.
Full pages: NEUROCRINE BIOSCIENCES INC and BIOGEN INC., or browse the full rankings.